Sudeep Pharma Recommends ₹1.50 Dividend; Appoints Auditors
Sudeep Pharma Ltd's board approved audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.50 per equity share (150%). They appointed M/s. Chetan Gandhi & Associates as Cost Auditor for FY 2026-27 and M/s H M Mehta & Associates as Secretarial Auditor for five years, commencing from FY 2026-27 until 2030-31, subject to shareholder approval at the upcoming AGM. The board meeting concluded on May 21, 2026.
Key Highlights
- Approved audited financial results for the year ended March 31, 2026.
- Recommended a final dividend of ₹1.50 per share (150%).
- Appointed M/s. Chetan Gandhi & Associates as Cost Auditor for FY 2026-27.
- Appointed M/s H M Mehta & Associates as Secretarial Auditor for 5 years.
- Secretarial Auditor appointment subject to shareholder approval.
Price Impact
More from SUDEEPPHRM
More in Board Meeting
Sambhv Steel Tubes Board Meeting on July 15, 2026 to Consider Fund Raising
Vineet Laboratories Board Meeting on July 15, 2026 for Audited Results
LTM (ex-LTIMindtree) Q1 strong: consol PAT +17% YoY to ₹1,469 Cr, revenue +18%, margins expand